First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?

Caterina Vivaldi, Francesca Salani, Giulia Rovesti, Irene Pecora, Silvia Catanese, Andrea Casadei-Gardini, Valentina Massa, Laura Bernardini, Laura Riggi, Kalliopi Andrikou, Giovanni Ilario Rapposelli, Vincenzo Formica, Monica Lencioni, Alfredo Falcone, Enrico Vasile, Lorenzo Fornaro

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Gemcitabine plus nab-paclitaxel (Gem-Nab) represents a standard first-line treatment for metastatic pancreatic cancer (mPC), but few data are available for elderly patients. We aimed to add evidence about safety and efficacy of Gem-Nab in this population.

METHODS: We collected data of 156 patients with mPC aged ≥65 years receiving Gem-Nab. Patients were stratified according to age: <70 (group 1: 65 patients) and ≥70 years (group 2: 91 patients).

RESULTS: The median age was 71 years (range: 65-87 years). The toxicity profile was similar between group 1 and 2, except for all-grade anaemia (92.1% vs. 78.7%, respectively; p = 0.04) and neurotoxicity (61.9% vs. 40.4%, respectively; p = 0.02), also as a result of a lower dose intensity of nab-paclitaxel (83.3% vs. 90.5%, respectively; p = 0.04) administered to oldest patients. The response rate was 25.6% (group 1 vs. 2: 20.0% vs. 29.7%; p = 0.12). After a median follow-up of 26.5 months, median overall survival (OS) and progression-free survival (PFS) were similar between the groups (p > 0.05). The starting dose of Gem-Nab did not affect PFS and OS (p > 0.05).

CONCLUSION: Gem-Nab is active and effective in older patients with mPC, with the results in line with the general mPC population enrolled in clinical trials. Mild dose modifications for elderly patients might be considered to improve safety without impairing efficacy.

Original languageEnglish
Pages (from-to)108-116
Number of pages9
JournalEur. J. Cancer
Volume137
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Aged
  • Aged, 80 and over
  • Albumins/pharmacology
  • Antimetabolites, Antineoplastic/pharmacology
  • Deoxycytidine/analogs & derivatives
  • Female
  • Humans
  • Male
  • Neoplasm Metastasis
  • Paclitaxel/pharmacology
  • Pancreatic Neoplasms/drug therapy

Fingerprint Dive into the research topics of 'First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?'. Together they form a unique fingerprint.

Cite this